<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516123</url>
  </required_header>
  <id_info>
    <org_study_id>CS3006-101</org_study_id>
    <nct_id>NCT03516123</nct_id>
  </id_info>
  <brief_title>A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, dose escalation &amp; expansion phase I study to evaluate the
      clinical safety, tolerability, PK, and preliminary efficacy of CS3006.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 30 days after last dose of CS3006</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>CS3006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CS3006 orally at specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS3006</intervention_name>
    <description>In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the dose expansion part, participants will receive CS3006 at specified dose level(s).</description>
    <arm_group_label>CS3006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with histologically or cytologically confirmed advanced or metastatic solid
             tumor(s) for which no effective standard therapy is available or tolerable.

          2. ECOG performance status of 0 or 1.

          3. Life expectancy â‰¥12 weeks.

          4. Able to swallow and retain oral medication.

          5. Subjects must have adequate organ function.

          6. Use of effective contraception.

        Exclusion Criteria:

          1. Subjects receiving anti-cancer therapy at the time of enrollment.

          2. Subjects who had prior chemotherapy, targeted therapy, immunotherapy or any other
             systemic anti-cancer treatment, within 14 days prior to the first dose of CS3006 or
             who has not recovered from adverse events due to a prior therapy.

          3. Receipt of any prior therapy with a MEK inhibitor.

          4. Use of any investigational anti-cancer drug within 28 days before the first dose of
             CS3006.

          5. Current use of a prohibited medication or use during treatment of CS3006.

          6. Current use of warfarin.

          7. Any condition that will interfere significantly with the absorption, distribution,
             metabolism, or excretion of drugs.

          8. History of retinal vein occlusion (RVO) or central serous retinopathy (CSR).

          9. Visible retinal pathology as assessed by ophthalmologic exam.

         10. Intraocular pressure &gt; 21mm Hg as measured by tomography.

         11. Glaucoma diagnosed within one month prior to the first dose of CS3006.

         12. Known brain metastasis or other CNS metastasis that is either symptomatic or
             untreated.

         13. Primary malignancy of CNS.

         14. Evidence of severe or uncontrolled systemic diseases.

         15. Subjects with clinically significant cardiovascular disease.

         16. QTc interval &gt;= 450 msecs for male or &gt;= 470 msecs for female

         17. Known history of HIV.

         18. Subjects with active Hepatitis B or C infection

         19. History of immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to CS3006.

        For more information regarding trial participation, please contact at
        cstonera@cstonepharma.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoyan Xing</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Queenie Yu</last_name>
    <phone>+862161097678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

